Abstract:Epithelial-mesenchymal transition (EMT) is a crucial step in tumor metastasis. Triple negative (TN) breast cancer, a high metastasis phenotype, has been verified to be associated with EMT. Melanoma associated antigen-A (MAGE-A) is exclusively expressed in cancers with high aggressiveness as well as unfavorable prognosis and likely to be associated with EMT of triple negative breast cancer (TNBC). The aim of the study is to analyze the expression profile of MAGE-A in breast cancer and the correlation between MAGE-A and EMT of TNBC. Immunohistochemistry (IHC) was performed to assess the prevalence of MAGE-A, vimentin, E-cadherin and beta-catenin in breast cancer tissues and correlate them with clinical pathological parameters. The association between MAGE-A and EMT markers was also evaluated. Scratch assay and transwell invasion assay were carried out to evaluate the impact of MAGE-A down-regulation on migration and invasion of the breast cancer cells. Real-time PCR was also conducted to evaluate alterations in EMT markers with decrease in MAGE-A. The results showed that MAGE-A was absent in normal tissue but expressed in tumor samples with the incidence of 49.17% (P=0.008). MAGE-A staining was higher in TNBC (76.47%, 13/17), followed by HER-2(+) (53.85%, 7/13) and Luminal set (43.33%, 39/90), and it was significantly correlated with ER (-), PR (-), HER-2 (-), lymph nodes involvement and higher histological grade (P<0.05). E-cadherin-positivity was frequent in Luminal set (94.44%, 85/90) and linked to ER (+), negative lymph nodes and lower histological grade (P<0.05). Vimentin expression was often observed in TNBC (70.59%, 12/17) and ER (-), PR (-), lymph nodes (+) groups (P<0.05). Expression of beta-catenin was prevalent in Luminal set (93.33%, 84/90) and correlated with ER (+), PR (+) and lower histological grade (P<0.05). MAGE-A was inversely associated with E-cadherin (P=0.011) and beta-catenin (P=0.048) but expressed in the same trend with vimentin (P=0.000). Migration and invasion of MDA-MB-231 were inhibited when MAGE-A decreased. Increase in epithelial markers and decline in mesenchymal indicators were also seen with MAGE-A reduction. Snail, Slug, ZEB1 and ZEB2 were also down-regulated. In conclusion, MAGE-A may be responsible for high aggressiveness and EMT of TNBC and can be a new choice for targeted therapy.

Development of Ligands and Degraders Targeting MAGE-A3

Proliferative effect of MAGE-A9 deletion mutant on human breast cancer MCF-7 cells

Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.

Research Advance of MAGE-A Gene Family in Tumor Growth

Biological functions of melanoma-associated antigens.

Structural Basis for Substrate Recognition and Chemical Inhibition of Oncogenic MAGE Ubiquitin Ligases

Maged1: Molecular Insights And Clinical Implications

Advances in Research of MAGE-A3

[Biological Functions of Melanoma-Associated Antigens (mages) in Cell Activities].

When MAGE Meets RING: Insights into Biological Functions of MAGE Proteins

Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer

Melanoma Antigen Gene Family in the Cancer Immunotherapy

Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer

Melanoma Antigen Family A (MAGE A) as Promising Biomarkers and Therapeutic Targets in Bladder Cancer

Abstract 6824: Secretion of MAGE-A3 and MAGE-A4 in cell lines and lung cancer

Proteomic Analysis Revealed the Potential Role of MAGE-D2 in the Therapeutic Targeting of Triple-Negative Breast Cancer

MAGE-A1 promotes melanoma proliferation and migration through C-JUN activation

MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases

MAGE-A is Frequently Expressed in Triple Negative Breast Cancer and Associated with Epithelial-Mesenchymal Transition

Establishment of MAGEC2‐knockout Cells and Functional Investigation of MAGEC2 in Tumor Cells